ERBB2 amplification was the most common predictive marker in gastroesophageal adenocarcinoma, and recent targeted therapy approvals and guideline updates had a significant impact for patients with cholangiocarcinoma and actionable findings in IDH1 (11.2%), FGFR2 (8.1%), or BRAF (1.8%) (Table 2). Here, IDH1 is linked to cholangiocarcinoma.